BRPI1007222A2 - agente de depleção de células b para tratamento de aterosclerose - Google Patents
agente de depleção de células b para tratamento de ateroscleroseInfo
- Publication number
- BRPI1007222A2 BRPI1007222A2 BRPI1007222A BRPI1007222A BRPI1007222A2 BR PI1007222 A2 BRPI1007222 A2 BR PI1007222A2 BR PI1007222 A BRPI1007222 A BR PI1007222A BR PI1007222 A BRPI1007222 A BR PI1007222A BR PI1007222 A2 BRPI1007222 A2 BR PI1007222A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell depletion
- treating atherosclerosis
- depletion agent
- agent
- atherosclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09290005 | 2009-01-06 | ||
| EP09305013 | 2009-01-07 | ||
| PCT/EP2010/050048 WO2010079161A1 (en) | 2009-01-06 | 2010-01-05 | A b cell depleting agent for the treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1007222A2 true BRPI1007222A2 (pt) | 2016-02-23 |
Family
ID=41651536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007222A BRPI1007222A2 (pt) | 2009-01-06 | 2010-01-05 | agente de depleção de células b para tratamento de aterosclerose |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20110275791A1 (pt) |
| EP (1) | EP2373339B1 (pt) |
| JP (1) | JP5828151B6 (pt) |
| KR (1) | KR20110117652A (pt) |
| CN (1) | CN102271710A (pt) |
| BR (1) | BRPI1007222A2 (pt) |
| CA (1) | CA2744670C (pt) |
| ES (1) | ES2630226T3 (pt) |
| WO (1) | WO2010079161A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104945379B (zh) * | 2009-06-12 | 2018-11-30 | Abivax公司 | 用于治疗过早衰老和尤其是早衰的化合物 |
| JP7012366B2 (ja) * | 2016-10-19 | 2022-02-14 | 公立大学法人横浜市立大学 | 抗動脈硬化剤及び動脈硬化の病態判定方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CN101928344B (zh) * | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| WO2004075789A2 (en) | 2003-02-26 | 2004-09-10 | Cook Incorporated | PROTHESIS ADAPTED FOR PLACEDd UNDER EXTERNAL IMAGING |
| MXPA05010778A (es) * | 2003-04-09 | 2005-12-12 | Genentech Inc | Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa. |
| US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| MXPA06006864A (es) | 2003-12-19 | 2006-08-23 | Genentech Inc | Deteccion de cd20 en la terapia de enfermedades autoinmunes. |
| JP5848861B2 (ja) * | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US20060188495A1 (en) * | 2005-01-13 | 2006-08-24 | Genentech, Inc. | Treatment method |
| AU2006308860B2 (en) | 2005-11-01 | 2012-01-12 | Novartis Ag | Uses of anti-CD40 antibodies |
| US8586822B2 (en) | 2007-11-02 | 2013-11-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for producing a non human model for aortic aneurysm |
| WO2010042548A2 (en) * | 2008-10-06 | 2010-04-15 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| US8318161B2 (en) * | 2009-03-06 | 2012-11-27 | Genentech, Inc. | Anti-oxidized LDL antibody formulation |
| US9688767B2 (en) * | 2013-03-15 | 2017-06-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of predicting survival time in myocardial infarction patients by measuring BAFF levels |
-
2010
- 2010-01-05 JP JP2011544056A patent/JP5828151B6/ja active Active
- 2010-01-05 ES ES10700019.2T patent/ES2630226T3/es active Active
- 2010-01-05 CA CA2744670A patent/CA2744670C/en active Active
- 2010-01-05 EP EP10700019.2A patent/EP2373339B1/en active Active
- 2010-01-05 US US13/143,440 patent/US20110275791A1/en not_active Abandoned
- 2010-01-05 CN CN2010800042396A patent/CN102271710A/zh active Pending
- 2010-01-05 WO PCT/EP2010/050048 patent/WO2010079161A1/en active Application Filing
- 2010-01-05 KR KR1020117015623A patent/KR20110117652A/ko not_active Application Discontinuation
- 2010-01-05 BR BRPI1007222A patent/BRPI1007222A2/pt not_active IP Right Cessation
-
2013
- 2013-03-08 US US13/790,771 patent/US20130224215A1/en not_active Abandoned
-
2019
- 2019-07-09 US US16/505,788 patent/US20190365890A1/en not_active Abandoned
-
2020
- 2020-06-16 US US16/902,518 patent/US20200376118A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20130224215A1 (en) | 2013-08-29 |
| CA2744670A1 (en) | 2010-07-15 |
| US20110275791A1 (en) | 2011-11-10 |
| EP2373339B1 (en) | 2017-04-19 |
| EP2373339A1 (en) | 2011-10-12 |
| WO2010079161A1 (en) | 2010-07-15 |
| CN102271710A (zh) | 2011-12-07 |
| KR20110117652A (ko) | 2011-10-27 |
| ES2630226T3 (es) | 2017-08-18 |
| US20190365890A1 (en) | 2019-12-05 |
| US20200376118A1 (en) | 2020-12-03 |
| JP2012514587A (ja) | 2012-06-28 |
| JP5828151B6 (ja) | 2018-09-19 |
| JP5828151B2 (ja) | 2015-12-02 |
| CA2744670C (en) | 2018-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013219A2 (pt) | método para o alvejamento-branqueamento enzimático têxtil | |
| BRPI0908970A2 (pt) | Método para controlar interferência em implementação de célula femto | |
| BRPI1014721A2 (pt) | métodos e dispositivos para cortar e raspar tecido | |
| BRPI0918894A2 (pt) | distribuição de conteúdo para dispositivo móvel | |
| IL225924A (en) | Dlbcl treatment | |
| BRPI1014981A2 (pt) | material para mancais de contato deslizante | |
| BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
| BR112013018679A2 (pt) | agente para o tratamento da alopecia | |
| BR112013016491A2 (pt) | método para tratamento de têxtil | |
| BR112012005036A2 (pt) | equipamento para o processamento de material de descarte. | |
| BR112012005247A2 (pt) | agente antifitoviral | |
| BRPI0911077A2 (pt) | método para tratamento de biomassa | |
| FI20125961A (fi) | Menetelmä myllyn käytöksi | |
| BRPI1008795A2 (pt) | processos de alquilação e de hidroconversão | |
| BR112014015551A8 (pt) | método para tratar lama e método para desidratação de lama | |
| BRPI1013361A2 (pt) | método para evitar e tratar hipermeabilidade. | |
| BRPI1013927A2 (pt) | métodos e composições para o tratamento de lúpus | |
| BRPI0924398A2 (pt) | perexilina, metodo de tratamento de hfnef e programa de tratamento para tratar hfnef | |
| BRPI1008016A2 (pt) | método para o tratamento de águas residuais | |
| CO6920300A2 (es) | Agente de dispersión para suspensiones sólidas | |
| BR112013009075A2 (pt) | método e arranjo para tratamento de polpa | |
| BRPI1009435A2 (pt) | tratamento para câncer no pâncreas | |
| BRPI1007222A2 (pt) | agente de depleção de células b para tratamento de aterosclerose | |
| BR112012001648A2 (pt) | método para tratar água residual | |
| BR112012014041A2 (pt) | sistemas e métodos para processamento de glicerol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |